Patent · US Active

Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles

US9549976B1 · kind B1 · utility

1Cited by
1References
18Claims
0Family size

Assignees

Inventors

Key dates

Filing dateNov 15, 2013
Grant dateJan 24, 2017
Priority date
Expiry dateNov 15, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2760/18234
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to virus-like particles of bacteriophage MS2 (MS2 VLPs) displaying peptide epitopes or peptide mimics of epitopes of Nipah Virus envelope glycoprotein that elicit an immune response against Nipah Virus upon vaccination of humans or animals. Affinity selection on Nipah Virus-neutralizing monoclonal antibodies using random sequence peptide libraries on MS2 VLPs selected peptides with sequence similarity to peptide sequences found within the envelope glycoprotein of Nipah itself, thus identifying the epitopes the antibodies recognize. The selected peptide sequences themselves are not necessarily identical in all respects to a sequence within Nipah Virus glycoprotein, and therefore may be referred to as epitope mimics VLPs displaying these epitope mimics can serve as vaccine. On the other hand, display of the corresponding wild-type sequence derived from Nipah Virus and corresponding to the epitope mapped by affinity selection, may also be used as a vaccine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.